“Brodalumab in the Treatment of Moderate-to-Severe Psoriasis in Patients Refractory to Anti-Interleukin-17A Therapies: Evaluation of Secondary Endpoints”. SKIN The Journal of Cutaneous Medicine, vol. 5, no. 5, Sept. 2021, pp. 524-9, https://doi.org/10.25251/skin.5.5.10.